How many JAK inhibitors in myelofibrosis?

Best Practice and Research: Clinical Haematology

Volumn 27, Issue 2, 2014, Pages 187-195

  Ferreira, Bruna Velosa ^a   Harrison, Claire ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

JAK 1; JAK 2; Momelotinib; Pacritinib; Ruxolitinib

Indexed keywords

2 [1 (4 FLUOROPHENYL)ETHYLAMINO] 4 (1 METHYL 1H PYRAZOL 4 YL) 6 (2 PYRAZINYLAMINO)PYRIDINE; 5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BEVACIZUMAB; BORTEZOMIB; BUPARLISIB; DACTOLISIB; EVEROLIMUS; FEDRATINIB; FRESOLIMUMAB; GANDOTINIB; GIVINOSTAT; GLASDEGIB; IMETELSTAT; INCB 039110; JANUS KINASE; JANUS KINASE INHIBITOR; MOMELOTINIB; N,N DICYCLOPROPYL 4 [(1,5 DIMETHYL 1H PYRAZOL 3 YL)AMINO] 6 ETHYL 1,6 DIHYDRO 1 METHYLIMIDAZO[4,5 D]PYRROLO[2,3 B]PYRIDINE 7 CARBOXAMIDE; PACRITINIB; PANOBINOSTAT; PATIDEGIB; PRACINOSTAT; RUXOLITINIB; SONIDEGIB; SUNITINIB; TOFACITINIB; UNCLASSIFIED DRUG; VORINOSTAT; 11-(2-PYRROLIDIN-1-YLETHOXY)-14,19-DIOXA-5,7,26-TRIAZATETRACYCLO(19.3.1.1(2,6).1(8,12))HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; BRIDGED COMPOUND; HISTONE DEACETYLASE INHIBITOR; JAK1 PROTEIN, HUMAN; JAK2 PROTEIN, HUMAN; JANUS KINASE 1; JANUS KINASE 2; N-(CYANOMETHYL)-4-(2-((4-(4-MORPHOLINYL)PHENYL)AMINO)-4-PYRIMIDINYL)BENZAMIDE; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ARTICLE; CHRONIC MYELOID LEUKEMIA; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MONOTHERAPY; MYELOFIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; ANTAGONISTS AND INHIBITORS; DRUG COMBINATION; GENE EXPRESSION; GENETICS; MUTATION; PATHOLOGY; PRIMARY MYELOFIBROSIS;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BENZAMIDES; BRIDGED COMPOUNDS; DRUG THERAPY, COMBINATION; GENE EXPRESSION; HISTONE DEACETYLASE INHIBITORS; HUMANS; JANUS KINASE 1; JANUS KINASE 2; MUTATION; PRIMARY MYELOFIBROSIS; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIMIDINES;

EID: 84927956341     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2014.07.010     Document Type: Review

References (60)

1. Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: Critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011; 29 (6) : 761-70 [Epub 2011/01/06].
2. Reilly JT, McMullin MF, Beer PA, et al. Guideline for the diagnosis and management of myelofibrosis. Br J Haematol 2012; 158 (4) : 453-71 [Epub 2012/06/02].
3. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113 (13) : 2895-901 [Epub 2008/11/08].
4. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366 (9) : 799-807 [Epub 2012/03/02].
5. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012; 366 (9) : 787-98 [Epub 2012/03/02].
6. Cervantes F, Vannucchi AM, Kiladjian JJ, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 2013; 122 (25) : 4047-53 [Epub 2013/11/01].
7. Verstovsek S, Gotlib J, Levy RS, et al. Long-term outcomes of ruxolitinib therapy in patients with myelofibrosis: 3-year update from COMFORT-I. Blood 2013; 122 (21) : 396.
8. Thiele J, Bueso-Ramos CE, SunW, et al. Effects of five-years of ruxolitinib therapy on bone marrow morphology in patients with myelofibrosis and comparison with best available therapy. Blood 2013; 122 (21) : 4055.
9. Wilkins BS, Radia D, Woodley C, et al. Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib. Haematologica 2013; 98 (12) : 1872-6 [Epub 2013/09/24].
10. Talpaz M, Jamieson C, Gabrail N, et al. Updated results from a randomized phase 2 dose-ranging study of the JAK2-selective inhibitor SAR302503 in patients with intermediate-2 or high-risk myelofibrosis (MF) . Haematol (Budap) 2013; 98 (s1) : 458 [abstract S1113].
11. Talpaz M, Jamieson C, Gabrail N, et al. Modulation of plasma cytokines and its association with clinical response to treatment with the JAK2-selective inhibitor SAR302503 in a phase 2 study of patients with myelofibrosis (MF) . Haematol (Budap) 2013; 98 (s1) : 117 [abstract p272].
12. Harrison CN, Cortes JE, Cervantes F, et al. Results of a randomized, double-blind, placebo-controlled phase III study (JAKARTA) of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis (MF) . Blood 2013; 122 (21) : 393.
13. Schaap NP, Zweegman S, Jourdan E, et al. Efficacy and safety of fedratinib (SAR302503/TG101348) in patients with intermediate-or high-risk myelofibrosis (MF) , Post-Polycythemia vera (PV) MF, or Post-Essential thrombocythemia (ET) MF previously treated with Ruxolitinib: Interim results from a phase II study (JAKARTA-2) . Blood 2013; 122 (21) : 661.
14. Pardanani A, Lasho T, Smith G, et al. CYT387, a selective JAK1/JAK2 inhibitor: In vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia 2009; 23 (8) : 1441-5.
15. Pardanani A, Laborde RR, Lasho TL, et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia 2013; 27 (6) : 1322-7.
16. Gotlib J, Gupta V, Roberts AW, et al. Update on the long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis. Blood 2013; 122 (21) : 108.
17. William AD, Lee AC, Blanchard S, et al. Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1 (2,6) . 1 (8,12) ]heptacosa-1 (25) ,2 (26) ,3,5,8,10,12 (27) ,16,21,23-decaene (SB1518) , a potent janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma. J Med Chem 2011; 54 (13) : 4638-58.
18. Komrokji R, Wadleigh M, Seymour J, et al. Results of a phase 2 study of pacritinib (SB 1518) , a novel oral JAK2 inhibitor, in patients with primary, post-polycythemia vera, and posy-essential thrombocythemia myelofibrosis. Blood 2011; 118 Abstract 282
19. Purandare AV, McDevitt TM, Wan H, et al. Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2. Leukemia 2012; 26 (2) : 280-8.
20. Roberts AW, Seymour JF, Burbury K, et al. BMS-911543, a selective JAK2 inhibitor: A multicenter phase 1/2a study in myelofibrosis. Blood 2013; 122 (21) : 664.
21. Nakaya Y, Shide K, Niwa T, et al. Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms. Blood cancer J 2011; 1 (7) : E29.
22. Changelian PS, Flanagan ME, Ball DJ, et al. Prevention of organ allograft rejection by a specific janus kinase 3 inhibitor. Science 2003; 302 (5646) : 875-8.
23. Manshouri T, Quintas-Cardama A, Nussenzveig RH, et al. The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation. Cancer Sci 2008; 99 (6) : 1265-73 [Epub 2008/05/17].
24. Ma L, Clayton JR, Walgren RA, et al. Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F. Blood cancer J 2013; 3: E109 [Epub 2013/04/16].
25. Mesa RA, Salama ME, Giles JLK, et al. Phase I study of LY2784544, a JAK2 selective inhibitor, in patients with myelofibrosis (MF) , polycythemia vera (PV) , and essential thrombocythemia (ET) . Blood 2013; 122 (21) : 665.
26. Talpaz M, Gupta V, Savona M, et al. An open-label, phase II study of the JAK1 inhibitor INCB039110 in patients with myelofibrosis. Blood 2013; 122 (21) : 663.
27. Deshpande A, Reddy MM, Schade GO, et al. Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms. Leukemia 2012; 26 (4) : 708-15 [Epub 2011/09/20].
28. Quintas-Cardama A, Verstovsek S. Molecular pathways: Jak/STAT pathway: Mutations, inhibitors, and resistance. Clin Cancer Res 2013; 19 (8) : 1933-40 [Epub 2013/02/15].
29. Tefferi A, Pardanani A. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc 2011; 86 (12) : 1188-91 [Epub 2011/10/29].
30. Caocci G, Murgia F, Podda L, et al. Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis. Leukemia 2014; 28 (1) : 225-7 [Epub 2013/08/10].
31. Wysham NG, Sullivan DR, Allada G. An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor. Chest 2013; 143 (5) : 1478-9 [Epub 2013/05/08].
32. Goldberg RA, Reichel E, Oshry LJ. Bilateral toxoplasmosis retinitis associated with ruxolitinib. N Engl J Med 2013; 369 (7) : 681-3 [Epub 2013/08/16].
33. Wathes R, Moule S, Milojkovic D. Progressive multifocal leukoencephalopathy associated with ruxolitinib. N Engl J Med 2013; 369 (2) : 197-8 [Epub 2013/07/12].
34. Heine A, Brossart P, Wolf D. Ruxolitinib is a potent immunosuppressive compound: Is it time for anti-infective prophylaxis? Blood 2013; 122 (23) : 3843-4 [Epub 2013/11/30].
35. Heine A, Held SA, Daecke SN, et al. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood 2013; 122 (7) : 1192-202 [Epub 2013/06/19].
36. Rudolph J, Cornez I, Brossart P, et al. The JAK1/JAK2 inhibitor ruxolitinib substantially affects NK cell biology. Blood 2013; 122 (21) : 16.
37. Wolschke C, Alchalby H, Ayuk F, et al. The Pan-JAK inhibitor ruxolitinib impairs T-cell activation, cytokine production and proliferation in vivo and in vitro. Blood 2013; 122 (21) : 2001.
38. Campanelli R, Fois G, Poletto V, et al. Decrease of T regulatory cells in patients with myelofibrosis receiving ruxolitinib. Blood 2013; 122 (21) : 4057.
39. Cornez I, Heine A, Brossart P, et al. CD4+ T cell functions are potently suppressed by the janus kinase 1/2 (JAK1/JAK2) inhibitor ruxolitinib. Blood 2013; 122 (21) : 2281.
40. Massa M, Rosti V, Campanelli R, et al. Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib. Leukemia 2014; 28 (2) : 449-51.
41. Kordasti SY, Seidl T, Abellan PP, et al. JAK inhibition reduces CD25 high CD27+ FOXp3+ T regulatory cells and causes a silencing of T effector cells in patients with myeloproliferative neoplasms whilst promoting a TH17 phenotype. Blood 2013; 122 (21) : 4092.
42. Guglielmelli P, Barosi G, Rambaldi A, et al. Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood 2011; 118 (8) : 2069-76.
43. Barosi G, Bordessoule D, Briere J, et al. Response criteria for myelofibrosis with myeloid metaplasia: Results of an initiative of the European myelofibrosis network (EUMNET) . Blood 2005; 106 (8) : 2849-53.
44. Tefferi A, Barosi G, Mesa RA, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for myelofibrosis research and treatment (IWG-MRT) . Blood 2006; 108 (5) : 1497-503.
45. Fiskus W, Verstovsek S, Manshouri T, et al. Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells. Mol Cancer Ther 2013; 12 (5) : 577-88.
46. Mascarenhas J, Lu M, Li T, et al. A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF) . Br J Haematol 2013; 161 (1) : 68-75.
47. Harrison CN, Kiladjian JJ, Passamonti F, et al. A phase 1B, dose-finding study of ruxolitinib plus panobinostat in patients with primary myelofibrosis (MF) , post-polycythemia vera MF (PPV-MF) or post-essential thrombocythemia MF. Haematol (Budap) 2012; 97 (s1) : 146 [abstract s0364].
48. Rambaldi A, Dellacasa CM, Finazzi G, et al. A pilot study of the histone-deacetylase inhibitor givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol 2010; 150 (4) : 446-55.
49. Andersen CL, Mortensen NB, Klausen TW, et al. A phase II study of vorinostat (MK-0683) in patients with primary myelofibrosis and post-polycythemia vera myelofibrosis. Haematologica 2014; 99 (1) : E5-7 [Epub 2014/01/16].
50. Quintas-Cardama A, Kantarjian H, Estrov Z, et al. Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis. Leuk Res 2012; 36 (9) : 1124-7.
51. Danilov AV, Relias V, Feeney DM, et al. Decitabine is an effective treatment of idiopathic myelofibrosis. Br J Haematol 2009; 145 (1) : 131-2. Epub 2009/01/13.
52. Quintas-Cardama A, Tong W, Kantarjian H, et al. A phase II study of 5-azacitidine for patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis. Leukemia 2008; 22 (5) : 965-70 [Epub 2008/04/04].
53. Mesa RA, Verstovsek S, Rivera C, et al. 5-azacitidine has limited therapeutic activity in myelofibrosis. Leukemia 2009; 23 (1) : 180-2 [Epub 2008/05/30].
54. Begna K, Laborde RR, Patnaik MM, et al. Imetelstat, a telomerase inhibitor, induces morphologic and molecular remissions in myelofibrosis and reversal of bone marrow fibrosis. Blood 2013; 122 (21) : 662.
55. Keller MD, Rampal RK, Shank K, et al. Improved efficacy of combination of JAK2 and hedgehog inhibitors in myelofibrosis. Blood 2013; 122 (21) : 666.
56. Mesa RA, Silver RT, Verstovsek S, et al. Single agent bevacizumab for myelofibrosis: Results of the myeloproliferative disorders research consortium trial. Haematologica 2013; 98 (9) : 1421-3 [Epub 2013/07/03].
57. Mesa RA, Verstovsek S, Rivera C, et al. Bortezomib therapy in myelofibrosis: A phase II clinical trial. Leukemia 2008; 22 (8) : 1636-8 [Epub 2008/02/29].
58. Barosi G, Gattoni E, Guglielmelli P, et al. Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition. Am J Hematol 2010; 85 (8) : 616-9 [Epub 2010/06/12].
59. Apostolidou E, Kantarjian H, Thomas D, et al. Phase II study of sunitinib in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Clin Lymphoma Myeloma Leuk 2010; 10 (4) : 281-4 [Epub 2010/08/17].
60. Mascarenhas J, Li T, Sandy L, et al. Anti-transforming growth factor-beta therapy in patients with myelofibrosis. Leuk Lymphoma 2014; 55 (2) : 450-2.